Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents

Background: The emergence and spread of SARS-CoV-2 throughout the world has created an enormous socioeconomic impact. Although there are several promising drug candidates in clinical trials, none is available clinically. Thus, the drug repurposing approach may help to overcome the current pandemic....

Full description

Bibliographic Details
Main Authors: Mohammad Z. Ahmed, Qamar Zia, Anzarul Haque, Ali S. Alqahtani, Omar M. Almarfadi, Saeed Banawas, Mohammed S. Alqahtani, Keshav L. Ameta, Shafiul Haque
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:Journal of Infection and Public Health
Subjects:
COVID-19
SARS-CoV-2
Docking and simulation
Aminoglycosides
Antibiotics
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034121000319

Internet

http://www.sciencedirect.com/science/article/pii/S1876034121000319

Similar Items